Shire to Combine with Baxalta in Deal Valued at About $32 Billion

Shire to Combine with Baxalta in Deal Valued at About $32 Billion


Shire Plc agreed to buy Baxalta Inc. for about $32 billion to become the world's biggest maker of so-called orphan drugs for rare diseases. The price includes 0.1482 of Shire's American depositary receipts and $18 in cash for each Baxalta share held, the Dublin-based drugmaker said in a statement.



from Biotech News